Fluorescent A
Adenosine receptor
Antagonist
Drug discovery
Flow cytometry
Fluorescent ligands
Receptor binding
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
25
03
2022
accepted:
24
05
2022
medline:
23
10
2023
pubmed:
11
6
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
Adenosine receptor (AR) ligands are being developed for metabolic, cardiovascular, neurological, and inflammatory diseases and cancer. The ease of drug discovery is contingent on the availability of pharmacological tools. Fluorescent antagonist ligands for the human A
Identifiants
pubmed: 35687212
doi: 10.1007/s11302-022-09873-3
pii: 10.1007/s11302-022-09873-3
pmc: PMC10539269
doi:
Substances chimiques
Purinergic P1 Receptor Antagonists
0
Fluorescent Dyes
0
Amines
0
Receptor, Adenosine A3
0
Receptor, Adenosine A2A
0
Adenosine A2 Receptor Antagonists
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-578Subventions
Organisme : Intramural NIH HHS
ID : ZIA DK031117
Pays : United States
Organisme : NIDDK NIH HHS
ID : ZIADK031117
Pays : United States
Informations de copyright
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Kidney Int. 2020 Mar;97(3):609-614
pubmed: 31784048
Chem Sci. 2020 Jun 17;11(26):6824-6829
pubmed: 33033597
Proc Natl Acad Sci U S A. 1986 Jun;83(11):4089-93
pubmed: 3012550
Nat Methods. 2017 Oct;14(10):987-994
pubmed: 28869757
Neuropharmacology. 2015 Nov;98:58-67
pubmed: 25890205
Front Endocrinol (Lausanne). 2020 Apr 28;11:262
pubmed: 32411098
J Med Chem. 1998 Jul 16;41(15):2835-45
pubmed: 9667972
FASEB J. 2011 Oct;25(10):3465-76
pubmed: 21715680
J Med Chem. 2018 May 24;61(10):4301-4316
pubmed: 29681156
J Med Chem. 2020 Mar 12;63(5):2656-2672
pubmed: 31887252
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866
Neuropharmacology. 2020 May 1;167:107741
pubmed: 31419398
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Org Biomol Chem. 2013 Sep 14;11(34):5673-82
pubmed: 23881285
Medchemcomm. 2017 Aug 1;8(8):1659-1667
pubmed: 29250307
J Med Chem. 2020 Apr 23;63(8):4334-4348
pubmed: 32271569
Angew Chem Int Ed Engl. 2022 May 23;61(22):e202115545
pubmed: 35174942
Commun Biol. 2020 Nov 27;3(1):722
pubmed: 33247190
Front Cell Neurosci. 2019 Mar 28;13:124
pubmed: 30983976
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Purinergic Signal. 2019 Jun;15(2):139-153
pubmed: 30919204
Biochem Pharmacol. 2012 Jun 1;83(11):1552-61
pubmed: 22402302
J Fluoresc. 1992 Dec;2(4):217-223
pubmed: 23772170
Nat Biotechnol. 2001 Apr;19(4):316-7
pubmed: 11283581
Acta Pharmacol Sin. 2019 Jun;40(6):717-723
pubmed: 30487651
Biochem Pharmacol. 2020 Dec;182:114214
pubmed: 32905795
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4673-8
pubmed: 15070776
Eur J Med Chem. 2020 Jan 15;186:111886
pubmed: 31787357
Bioconjug Chem. 2007 Sep-Oct;18(5):1593-603
pubmed: 17705414
J Med Chem. 2020 Nov 12;63(21):12196-12212
pubmed: 32667814
Cell. 2017 Feb 23;168(5):867-877.e13
pubmed: 28235198
ACS Chem Biol. 2019 May 17;14(5):934-940
pubmed: 31030512
Bioconjug Chem. 2011 Jun 15;22(6):1115-27
pubmed: 21539392
Biochem Pharmacol. 2021 May;187:114311
pubmed: 33130128
Medchemcomm. 2018 Oct 18;9(11):1920-1932
pubmed: 30568760
Org Biomol Chem. 2020 Apr 1;18(13):2459-2467
pubmed: 32167123
Cells. 2020 May 12;9(5):
pubmed: 32408534
Br J Pharmacol. 2010 Feb;159(4):772-86
pubmed: 20105183
J Neurochem. 2012 Nov;123(3):373-84
pubmed: 22924752
Cells. 2020 Jul 21;9(7):
pubmed: 32708189
ACS Med Chem Lett. 2022 Mar 02;13(4):623-631
pubmed: 35450351
ACS Cent Sci. 2019 Sep 25;5(9):1602-1613
pubmed: 31572787